Skip To Main Content
Susana Campos on Muck Rack

Susana Campos

As seen in: Nature, Wiley Online Library, MDPI, Medscape, EIN News, Emerald Publishing, Dialnet - Universidad de La Rioja, Cult Beauty, ONCOLOGY journal, OncLive and
https://www.facebook.com/

Get in touch with Susana

Contact Susana, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Managing Multifocal BCLC-C HCC With Portal Vein Invasion and Variceal History

|
By Susana Campos, Rachna T Shroff, James Harding Verified
| ONCOLOGY journal Verified
Opinion|Videos|August 28, 2026 Author(s)Rachna T. Shroff, MD, MS, FASCO, James J. Harding, MD, Lipika Goyal, MD In the first clinical scenario of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), Team Deep-Dish Pizza manages a 67-year-old woman with hepatitis B cirrhosis and BCLC stage C disease, multifocal bilobar tumors with branch portal vein invasion (Vp3), Child-Pugh A6, ALBI grade 2, and an elevated alpha-fetoprotein level.
Open in Who Shared View Duplicates (5) Issue with article?

How Significant is the Approval of Daraxonrasib in Pancreatic Cancer?

|
By Susana Campos, Tim Cortese, Ariana Pelosci Verified
| ONCOLOGY journal Verified
Since the first reporting of overall survival (OS) data from the phase 3 RASolute 302 trial (NCT06625320), a near doubling of OS with daraxonrasib (Rasonque) vs standard of care, patients and clinicians have been aware that daraxonrasib represented a real advancement in the treatment of not just pancreatic cancer, but oncology.1 About 2 months later, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, when Brian M.
Open in Who Shared Issue with article?

sNDA for Gedatolisib Submitted to FDA in PIK3CA-Mutant Breast Cancer

|
By Susana Campos, Ariana Pelosci Verified, Roman Fabbricatore
| ONCOLOGY journal Verified
A supplemental new drug application (sNDA) has been submitted to the FDA for gedatolisib (Revtorpyk) in combination with fulvestrant (Faslodex), with or without palbociclib (Ibrance), for adults with hormone receptor (HR)-positive, HER2-negative (HER2–), locally advanced or metastatic breast cancer harboring a PIK3CA mutation who have progressed on at least 1 line of endocrine therapy, according to a press release from Celcuity.1 If approved, gedatolisib would become the first therapy for...
Open in Who Shared Issue with article?
See all 53 licensed articles (79 Total)